Screener
Immix Biopharma, Inc. IMMX Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating Leases | ||
| Operating lease right-of-use assets | $927,728 | $966,917 |
| Right of use liability operating lease current portion | $125,392 | $139,339 |
| Right of use liability operating lease long term | 912,343 | 933,625 |
| Total operating lease liabilities | $1,037,735 | $1,072,964 |
Document
FAQ
- What is Immix Biopharma, Inc.'s operating lease liabilities (total)?
- Immix Biopharma, Inc. (IMMX) reported operating lease liabilities (total) of $1.04M in Q1 2026.
- How has Immix Biopharma, Inc.'s operating lease liabilities (total) changed year-over-year?
- Immix Biopharma, Inc.'s operating lease liabilities (total) decreased by 2.0% year-over-year, from $1.06M to $1.04M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.
Ask your AI about Immix Biopharma, Inc.'s operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude